Two Decades of Orphan Product Development

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2002 Oct 3

PMID 12360259

Citations 45

Authors

Marlene E Haffner

Janet Whitley

Marie Moses

Affiliations

Soon will be listed here.

Abstract

Over the past 20 years, incentives of the Orphan Drug Act (ODA), the largest single source of extramural clinical grants at the US Food and Drug Administration, have had a substantial impact on public health. ODA incentives have contributed to the development of many innovative biotechnology products, and as our understanding of the human genome evolves, it is anticipated that pharmacogenomics will result in the identification of more 'orphan diseases'.

Citing Articles

Complement-targeted therapeutics: Are we there yet, or just getting started?.

Ricklin D Eur J Immunol. 2024; 54(12):e2350816.

PMID: 39263829 PMC: 11628912. DOI: 10.1002/eji.202350816.

Pharmaceutical policy and innovation for rare diseases: A narrative review.

Ruiz A, Large K, Moon S, Vieira M F1000Res. 2024; 12:211.

PMID: 38778810 PMC: 11109548. DOI: 10.12688/f1000research.130809.2.

Rare diseases: a challenge for medicine and public health.

Fehr A, Prutz F J Health Monit. 2024; 8(4):3-6.

PMID: 38235014 PMC: 10790412. DOI: 10.25646/11826.

Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan.

Alewaidat H, Bataineh Z, Bani-Ahmad M, Alali M, Almakhadmeh A F1000Res. 2023; 12:741.

PMID: 37822316 PMC: 10562777. DOI: 10.12688/f1000research.130388.1.

Children with a rare congenital genetic disorder: a systematic review of parent experiences.

von der Lippe C, Neteland I, Feragen K Orphanet J Rare Dis. 2022; 17(1):375.

PMID: 36253830 PMC: 9575260. DOI: 10.1186/s13023-022-02525-0.